Skip Page Header

Home > Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs.

Grebely, Jason and Larney, Sarah and Peacock, Amy and Colledge, Samantha and Leung, Janni and Hickman, Matthew and Vickerman, Peter and Blach, Sarah and Cunningham, Evan and Dumchev, Konstantin and Lynskey, Michael and Stone, Jack and Trickey, Adam and Razavi, Homie and Mattick, Richard P and Farrell, Michael and Dore, Gregory J and Degenhardt, Louisa (2019) Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction , 114 , (1) , pp. 150-166.

BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional, and country-levels.

METHODS: Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These data were combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV.

RESULTS: There are an estimated 6.1 million [95% uncertainty interval (UI) 3.4-9.2] people with recent injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic prevalence; UI 31.6-47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI 1.0-2.1), Eastern Europe (1.5 million, UI 0.7-2.4), and North America (1.0 million, UI 0.4-1.7). People with recent injecting drug use comprise an estimated 8.5% (UI 4.6-13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI 11.7-56.7), Latin America (22.0%, UI 15.3-30.4), and Eastern Europe (17.9%, UI 8.2-30.9).

CONCLUSIONS: Although globally about forty percent of people with recent injecting drug use are living with hepatitis C virus (HCV) and almost nine percent of all HCV infections globally occur among people with recent injecting drug use, there is wide variation among countries and regions.


Item Type
Article
Publication Type
Irish-related, International, Article
Drug Type
Substances (not alcohol/tobacco), Opioid
Intervention Type
Harm reduction
Date
2019
Page Range
pp. 150-166
Publisher
Wiley
Volume
114
Number
1
EndNote
Related URLs

Click here to request a copy of this literature

Repository Staff Only: item control page